{"organizations": [], "uuid": "bd7596c8cee8493cbc48362a7171b0a748329a1e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-kalvista-pharmaceuticals-commences/brief-kalvista-pharmaceuticals-commences-two-clinical-trials-idUSASB0BZVQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Kalvista Pharmaceuticals Commences Two Clinical Trials", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T14:32:00.000+02:00", "replies_count": 0, "uuid": "bd7596c8cee8493cbc48362a7171b0a748329a1e"}, "author": "", "url": "https://www.reuters.com/article/brief-kalvista-pharmaceuticals-commences/brief-kalvista-pharmaceuticals-commences-two-clinical-trials-idUSASB0BZVQ", "ord_in_thread": 0, "title": "BRIEF-Kalvista Pharmaceuticals Commences Two Clinical Trials", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-kalvista pharmaceuticals commences two clinical trials reuters", "sentiment": "negative"}, {"name": "kalvista pharmaceuticals inc", "sentiment": "none"}, {"name": "kalvista pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 33 PM / Updated 8 minutes ago BRIEF-Kalvista Pharmaceuticals Commences Two Clinical Trials Reuters Staff \nJan 5 (Reuters) - Kalvista Pharmaceuticals Inc: * KALVISTA PHARMACEUTICALS COMMENCES TWO CLINICAL TRIALS \n* KALVISTA PHARMACEUTICALS INC - TOP-LINE RESULTS ARE EXPECTED IN SECOND HALF OF 2019 FOR KVD001 \n* KALVISTA PHARMACEUTICALS INC - EXPECTS TO PROVIDE AN UPDATE ON STATUS AND PROGRESS OF HAE PORTFOLIO, INCLUDING KVD900, IN MID-2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-05T14:32:00.000+02:00", "crawled": "2018-01-05T14:48:58.004+02:00", "highlightTitle": ""}